Biogen BIIB Due from unconsolidated joint business
Due from unconsolidated joint business at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept biib:DueFromUnconsolidatedJointBusiness.
The official record: Biogen’s 10-K, filed February 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's due from unconsolidated joint business.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's due from unconsolidated joint business?
- Biogen (BIIB) reported due from unconsolidated joint business of $524.6M in Q4 2025.
- How has Biogen's due from unconsolidated joint business changed year-over-year?
- Biogen's due from unconsolidated joint business increased by 13.1% year-over-year, from $464M to $524.6M.
- What is the long-term trend for Biogen's due from unconsolidated joint business?
- Over 5 years (2020 to 2025), Biogen's due from unconsolidated joint business has grown at a 4.9% compound annual growth rate (CAGR), from $413.5M to $524.6M.
- What does due from unconsolidated joint business mean?
- This represents receivables or amounts owed to the company arising from collaborative arrangements or joint ventures that are not consolidated in the financial statements. For Biogen, this often relates to profit-sharing or cost-sharing agreements with partners like Roche or Eisai. It highlights the financial interdependencies inherent in the company's collaborative business model.